Acanthosis Nigricans
Clinical guidelines for managing hyperpigmented velvety plaques, evaluating insulin resistance and IGF-1 receptor parameters, and reviewing topical keratolytics.
Table of Contents
🧠 Standard of Care & Symptoms
Acanthosis Nigricans (AN) is a common, dermatological manifestation of systemic metabolic dysfunction, characterized by dark, thickened skin plaques.
- Presentation: Cutaneous lesions are characterized by symmetric, hyperpigmented, velvety, hypertrophic plaques.
- Anatomical Distribution: Primarily affects intertriginous (skin-fold) areas: the posterior and lateral neck, axillae, groin, antecubital and popliteal fossae, and umbilical region.
- Associated Signs: Acrochordons (skin tags) are frequently found within the affected regions.
- Etiology: Most commonly associated with insulin resistance secondary to obesity, type 2 diabetes mellitus, or metabolic syndrome. It can also be drug-induced (e.g. systemic corticosteroids, niacin, oral contraceptives). Rarely, it presents as a **paraneoplastic syndrome** (malignant acanthosis nigricans) secondary to an underlying gastric adenocarcinoma.
🔬 Diagnostics & Insulin Pathophysiology
Diagnosis is clinical, but lab screenings are critical to evaluate underlying metabolic or malignant disease.
- Metabolic Profiling: Fasting blood glucose, HbA1c, and fasting plasma insulin levels are obtained to evaluate for insulin resistance.
- H&E Histopathology: A skin biopsy shows:
- Marked **hyperkeratosis** (thickening of the outer stratum corneum).
- **Papillomatosis** (projection of dermal papillae upwards).
- Minimal or no increase in melanocytes; the dark clinical appearance is primarily caused by hyperkeratosis, which traps light and makes the thickened skin appear pigmented.
IGF-1R Cross-Reaction & paraneoplastic EGFR Pathways
The skin thickening is driven by systemic growth factors cross-reacting with epidermal cell receptors:
- Insulin-IGF-1R Cross-Reaction (Metabolic): In obesity and type 2 diabetes, compensatory hyperinsulinemia results in high circulating insulin. At these high concentrations, insulin binds directly to the **insulin-like growth factor-1 receptor (IGF-1R)** on keratinocytes and dermal fibroblasts. This binding activates the intracellular **MAPK/ERK** and **PI3K/Akt** signaling pathways, driving cell proliferation and hyperplasia.
- TGF-α/EGFR Activation (Malignant Paraneoplastic): In malignant AN, tumor cells (commonly gastric adenocarcinoma) secrete high levels of **transforming growth factor-alpha (TGF-α)** or **epidermal growth factor (EGF)**. These factors travel via the blood and bind to the **epidermal growth factor receptor (EGFR)** on keratinocytes, triggering rapid-onset epidermal hyperplasia.
💊 Weight Management & Topical Keratolytics
Primary management focuses on treating the underlying systemic cause. Topical therapies provide cosmetic improvement by thinning the plaques.
- Systemic Treatment (Insulin Sensitization): Weight loss through caloric restriction and regular exercise increases insulin sensitivity. Pharmacological management with Metformin reduces circulating insulin.
- Topical Keratolytics & Retinoids:
- *Topical Retinoids (Tretinoin 0.05% cream):* Normalizes epidermal cell turnover and reduces hyperkeratosis.
- *Ammonium Lactate 12% lotion:* An alpha-hydroxy acid that hydrates skin and promotes desquamation of thickened sheets.
- *Salicylic Acid:* A beta-hydroxy acid that dissolves intercellular lipids to thin plaques.
🔬 Active Clinical Trials
Clinical trials are currently evaluating next-generation topical keratolytic agents, systemic insulin sensitizers, and paraneoplastic biomarkers.
A Phase II trial evaluating a novel topical EGFR pathway modulator designed to directly inhibit local epidermal proliferation.
Key Inclusion: Age 18 to 65, clinically confirmed moderate-to-severe Acanthosis Nigricans affecting the posterior neck or axillae, and stable body weight for ≥ 6 months.Testing a combination topical formulation containing a retinoid and a lipid-dissolving keratolytic agent for moderate-to-severe neck plaques.
Key Inclusion: Age ≥ 12, diagnosed with bilateral symmetric Acanthosis Nigricans of the neck/axillae, and willing to avoid other exfoliating therapies.Evaluating the resolution kinetics of acanthosis nigricans plaques under GLP-1 receptor agonist therapy in obese adolescents.
Key Inclusion: Age 12 to 19, body mass index (BMI) ≥ 95th percentile, documented insulin resistance with visible acanthosis nigricans, and initiating GLP-1 therapy under pediatric endocrinology.🗺️ Next Steps After Diagnosis
If you have recently been diagnosed with Acanthosis Nigricans, establish these medical pathways:
- Perform an HbA1c and Fasting Glucose Screen: Consult your primary care physician to rule out undiagnosed pre-diabetes or type 2 diabetes.
- Initiate Lifestyle Interventions: Focus on dietary changes and aerobic exercise to improve insulin sensitivity, which is the most effective way to clear skin plaques.
- Apply Topical Keratolytics: Apply ammonium lactate or salicylic acid cream daily to reduce the thickness and velvet texture of the plaques.
- Rule Out Atypical Triggers: If you are not overweight and develop sudden, rapidly spreading plaques on your palms, soles, or face, seek urgent evaluation to rule out paraneoplastic signs.
❓ Patient FAQ
Q: Why does insulin resistance cause my skin to thicken and turn dark?
A: In insulin resistance, your pancreas produces high amounts of insulin to manage blood sugar. At high concentrations, insulin cross-reacts with **insulin-like growth factor-1 receptors (IGF-1R)** on keratinocytes (skin cells) and fibroblasts. This binds to the receptors and stimulates rapid proliferation of skin cells, leading to thick, velvety plaques.
Q: Can I scrub or bleach the dark spots off?
A: No. Scrubbing vigorously with sponges or using skin bleaching creams will not resolve acanthosis nigricans. In fact, aggressive scrubbing can cause friction, leading to further thickening (lichenification) and worsening of the lesions. The darkness is due to the thickness of the skin layers trapping light, not excess melanin, so skin bleaches are ineffective.
Get the Free 2026 Clinical AI Directory
Email us at caleb@openphr.org to receive our exclusive directory of over 150 open-source models and clinical trial databases.